München (ots) - Wenn es um den Einkauf von Luxuswaren wie Uhren und Schmuck geht, setzen Schweizer ...
Biosign Certified for Non-invasive Blood Glucose Monitoring
Toronto (ots/PRNewswire) - Biosign Technologies Inc. (CNSX: BIO) ("Biosign" or the "Company") today announced it has been assessed and certified as meeting the requirements of ISO 9001:2008, ISO 13485-2003, and Directive 93/42/EEC ("CE Mark") for automated wrist blood pressure and blood glucose monitors with computer controls. The certificates allow Biosign to add non-invasive blood glucose monitoring to its offerings in the European Union and other regions that recognize these certifications.
Practically, UFIT(R) TEN-20 is a blood pressure monitor that also reads blood glucose. There is no additional hardware. Measurements are completely non-invasive, with results verifiable for accuracy and relevance.
"Researchers have attempted for years to find a solution that can eliminate the need for pricking the skin and drawing blood to measure glucose levels", said Peter Tassiopoulos, Biosign's Chief Operating Officer. "UFIT(R) TEN-20 solves this issue and, more importantly, it keeps an audit trail of every measurement taken for future reference."
The company is scaling resources for support and manufacturing to prepare for the anticipated demand by the market for the newly certified capability of the UFIT(R) system. "We can now proceed confidently on executing our ambitious plans for 2010." said Radu Leca, President and CEO of Biosign.
About Biosign Technologies Inc.
Biosign provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT(R) medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign please visit http://www.biosign.com
The CNSX has neither approved nor disapproved the contents of this press release.
For further information: Radu Leca, President & CEO, Biosign Technologies Inc., +1-416-218-9800 ext. 234, email@example.com
ots Originaltext: Biosign Technologies Inc.
Im Internet recherchierbar: http://www.presseportal.ch
CONTACT: For further information: Radu Leca, President & CEO,
BiosignTechnologies Inc., +1-416-218-9800 ext. 234, firstname.lastname@example.org